Effects of levodopa/carbidopa intestinal gel versus oral levodopa/carbidopa on B vitamin levels and neuropathy

Sebastian Loens | Elena Chorbadzhieva | Alexandra Kleimann | Dirk Dressler | Christoph Schrader

Abstract

Objectives: To determine the possible interactions between levodopa therapy and plasma levels of B vitamins in patients with advanced idiopathic Parkinson’s disease (IPD) in the context of either oral levodopa therapy or levodopa/carbidopa intestinal gel (LCIG). Secondly, to determine the prevalence of neuropathy and its relation to plasma levels of B vitamins and homocysteine.

Methods: Medication doses, neurographies, and serum levels of pyridoxine, cobalamin, folate, and homocysteine of eight LCIG and 13 orally treated advanced IPD patients matched for age, Hoehn & Yahr stage, and UPRDS III were collected. This data was analyzed for correlation with daily levodopa dose (LDD).

Results: LCIG patients had a longer disease duration and higher LDD. All LCIG patients and most orally treated patients had sensorimotor axonal polyneuropathy. Of all plasma vitamin levels, pyridoxine was decreased most and significantly lower in the LCIG group. Cobalamin and folate, however, were within the lower reference range, and homocysteine highly elevated, all without any significant difference between both groups. LDD correlated significantly with pyridoxine deficiency ($p = .02$) irrespective of the route of application and with hyperhomocysteinemia in the LCIG group ($p = .03$). At LDDs above 2,000 mg, pyridoxine deficiency was almost always detectable.

Conclusions: Pyridoxine deficiency and hyperhomocysteinemia are dependent on the daily levodopa/carbidopa dose, while levels of cobalamin and folate are not. The mode of application of levodopa/carbidopa has no impact on B-vitamin levels. Neuropathy is very frequent in advanced IPD; however, it remains to be investigated further whether neuropathy is more frequent in LCIG than in orally levodopa/carbidopa-treated advanced IPD patients.

Keywords: carbidopa, cobalamin, folate, levodopa, neuropathy, Parkinson’s disease, pyridoxine

1. INTRODUCTION

Since more than 40 years, levodopa is the most effective treatment for idiopathic Parkinson’s disease (IPD), but due to its short plasma half-life it causes pulsatile striatal receptor stimulation, and thereby—on the long run—motor side effects such as dyskinesias and motor fluctuations (Olanow, Obeso, & Stocchi, 2006). Continuous jejunal infusion of levodopa/carbidopa intestinal gel (LCIG) via a percutaneous
As neuropathy occurs in levodopa-treated IPD, most researchers have concentrated on plasma changes in the substrates of the levodopa metabolism. Briefly, levodopa is metabolized via catecholamine-O-methyltransferase (COMT) to 3-O-methyl-dopa. This step requires a methyl group from S-adenosyl-methionine (SAM). The further metabolism leads to the formation of homocysteine, which is either remethylated to methionine in a cobalamin- (vitamin B12) and folate- (vitamin B9)-dependent reaction, or metabolized to cysteine. This latter step requires pyridoxine (vitamin B6) as a cofactor. Pyridoxine is also cofactor in the decarboxylation of levodopa to dopamine (Figure 1).

Cobalamin deficiency as a potential cause of neuropathy in IPD has been investigated extensively, but with conflicting results: in levodopa-treated IPD patients, cobalamin has been shown to be lower in those with neuropathy than in those without it (Ceravolo et al., 2013; Mancini et al., 2014); some researchers have found an association between cobalamin levels and levodopa doses (Rajabally & Martey, 2013; Toth et al., 2010), but this finding could not be confirmed by others (Mancini et al., 2014). Also folate deficiency (Rajabally & Martey, 2013) and levodopa itself, especially LCIG and its ingredients or its way of resorption (Jugel et al., 2013), have been suspected to be involved in the development of neuropathy in IPD.

Pyridoxine deficiency has rarely been studied systematically in this context, although case reports have described a possible association (Klostermann, Jugel, Muller, & Marzinik, 2012; Urban et al., 2010). We too have observed dramatic changes of pyridoxine levels and just a mild decrease in cobalamin and folate in one of our patients in the first months after starting LCIG. This case was associated with subacute neuropathy (case 1, see below). This observation led us to assess the rest of our LCIG-treated patients with respect to plasma levels of B vitamins, homocysteine, and neuropathy, and to compare their data to orally treated controls.

The objectives of this study were to determine whether the mode of levodopa application has an influence on plasma levels of pyridoxine, folate, cobalamin, and homocysteine as possible triggers of neuropathy. Next, we wanted to assess whether LCIG treatment is associated with a higher incidence of neuropathy than oral pharmacotherapy in patients with advanced IPD.

2 MATERIALS AND METHODS

We searched our hospital database for data of advanced IPD patients treated either with LCIG or with oral dopaminergic drugs that had been hospitalized between January 2012 and December 2014 and for which plasma levels of pyridoxine (vitamin B6) were available. Vitamin levels were obtained irrespective of the cause of hospitalization, but only from those IPD patients that were taken care of by our movement disorders team.

For these identified patients, clinical data including gender, age, duration of IPD, Hoehn & Yahr stage (H&Y), UPDRS III in On condition, and current medication were collected. Of special interest were daily doses of levodopa (LDD); for other dopaminergic drugs, daily levodopa equivalent doses (LEDD) were calculated (Grosset, Needleman, Macphee, & Grosset, 2004; Tomlinson et al., 2010). In order to investigate whether both groups were comparable with regard to their dopaminergic demand, for LCIG patients current LDD/LEDD as well as the latest LDD/LEDD before starting LCIG treatment were obtained. All available plasma levels of folate, cobalamin, and homocysteine, and neurographies were collected. These plasma levels had originally been determined as a part of a routine laboratory testing in advanced IPD and therefore had been assessed independently of the presence of clinical or electrophysiological signs of neuropathy. Only patient data with results (clinical data, laboratory values and electrophysiology study results) obtained from the same time point were included into the analysis.

Only neurographies which included a complete exam with unilateral median, peroneal, tibial, and sural nerve were included, and were assessed with regard to motor and sensory conduction velocity, and amplitudes of the compound muscle action potential, or antidromic sensory potential, respectively. Neuropathy was defined as abnormal values for either conduction velocity or amplitudes in more than one nerve.

Statistical analyses were performed using GraphPad Prism 5.0 (GraphPad Software Inc., La Jolla, CA). Student’s t test and Mann-Whitney U tests were performed for clinical and demographic comparisons between the LCIG and orally treated patients. Significance was set at $p < .05$ for all analyses. Correlations between LDD/LEDD and vitamin plasma levels were assessed using Spearman’s correlation.
Analysis of this data was approved by the local ethics committee; all subjects gave informed consent to have their data analyzed anonymously in this study.

3 | RESULTS

In the period between 2012 and 2014, we identified 22 IPD patients treated with LCIG and 42 orally treated patients who had been admitted to our clinic. Thirteen LCIG patients had to be excluded because vitamin levels were unavailable, and one because LCIG therapy had been stopped 3 months before admission. Of those eight patients enrolled, six LCIG patients had been admitted because of technical complications of the PEG-tube system, two patients because of subacute neuropathy. In 13 of the 42 orally treated patients, vitamin levels were available, and all of them had been admitted to optimize medical treatment of motor fluctuations, and none because of neuropathy or psychiatric complications. In the LCIG group, four patients had STN DBS; in one of them, it had been terminated due to intolerable side effects when LCIG was initiated. In the medical treatment group, two had ongoing STN DBS.

Both groups did not differ regarding gender, age, and motor impairment as measured by UPDRS III (on) and H&Y. Disease duration was slightly longer in the LCIG group, yet this difference did not reach significance (Table 1). Patients in the LCIG group had a significantly higher need for dopaminergic drugs even before the start of LCIG infusion therapy (Table 1, Figure 2, Mann–Whitney U test). Two patients were on 24/7 LCIG infusion. Their LDD was 2,429 ± 960, but not significantly higher than the LDD of the 16 infusion patients (1,917 ± 1,048).

The change from oral treatment to LCIG had led to a further significant increase of LDD (before LCIG 1,286 ± 269 mg/day, during LCIG 2,342 ± 956 mg/day, p = .0021). LEDD increased as well (before LCIG 865.8 ± 567 mg/day, during LCIG 2,360 ± 1,064 mg/day), however, this was not significant (two-sided Wilcoxon test). As a result, LDD and LEDD were significantly higher in the LCIG group than in the orally treated group at the point of laboratory assessment (Figure 2, Mann–Whitney U test).

In six out of eight LCIG patients and 11 out of 13 orally treated patients, electrophysiology data was available. All patients in the LCIG group showed neuropathy: in fact, it occurred in virtually all examined peripheral nerves. With one exception, it was axonal sensory or sensorimotor neuropathy, that is, amplitudes of sensory or motor responses were either low or undetectable at all. In the oral treatment group, axonal sensory or sensorimotor neuropathy was found in eight of 11 patients, but compared to LCIG patients, it was generally milder with respect to the extent of axonal damage as well as to the number of affected nerves (Table 2).

Of all plasma vitamin levels, pyridoxine was decreased most, and it was significantly lower in the LCIG group. All other parameters did not differ between the two groups: cobalamin and folate were within the lower reference range, and homocysteine highly elevated in both groups (Table 1, Figure 3). LEDD correlated significantly with the decrease in pyridoxine levels (r = −0.49, p = .02) in all patients, and with the increase in homocysteine levels in the LCIG group (r = 0.78; p = .03), but with none of the other plasma levels (Spearman’s correlation coefficient, Figure 4).

The two cases of subacute axonal sensorimotor neuropathy in the LCIG group deserve special mentioning.

Case 1 was a 64-year-old female patient with a history of IPD for 14 years and severe motor fluctuations with a rapid switch between Off and heavy dyskinesia despite a combination of levodopa/carbidopa, entacapone, rotigotine, STN DBS, and apomorphine injections on a PRN basis. Before LCIG, she had an LDD of 1,450 mg and an LEDD of 2,990 mg. When LCIG was started, STN DBS was terminated; LEDD increased with LDD increase (Table 1). LEDD correlated significantly with the decrease in pyridoxine levels (r = −0.49, p = .02) in all patients, and with the increase in homocysteine levels in the LCIG group (r = 0.78; p = .03), but with none of the other plasma levels (Spearman’s correlation coefficient, Figure 4).
because of intolerable side effects, and the dopamine agonists and COMT inhibition were discontinued resulting in a 16 hr LCIG monotherapy with an LDD of 3,860 mg. With this unusually high LDD, she was continuously in an On condition with no or mild dyskinesia, able to walk without a stroller at any time, and was very pleased with the result. Three months after LCIG had been started, she presented with a 2-week history of sensory ataxia with astasia/abasia. Neurographies had revealed reduced amplitudes (i.e., axonal damage) before LCIG; however, 3 months later, no response whatsoever could be found anymore. Pyridoxine had dropped from 5.0 μg/L to below the threshold of detection (i.e., <1.5 μg/L), and homocysteine had shot up from 16.2 to 309.8 μmol/L. Cobalamin had dropped from 441.9 ng/L to 223 ng/L, and folate from >20 μg/L to 2.2 μg/L. LCIG was immediately stopped and replaced by subcutaneous apomorphine infusion; pyridoxine, cobalamin, and folate were substituted intravenously. However, the patient died from cerebral infarction one week after admission.

Case 2 was a 57-year-old male patient suffering from IPD for 14 years. His pre-LCIG, LDD, and LEDD could not be obtained; however, 13 months after starting LCIG, he developed paresthesias in all limbs in a period of 4 weeks at an LDD of 3,108 mg. Neurographies revealed pronounced axonal sensory damage. Pyridoxine was <1.5 μg/L, homocysteine was 83.3 μmol/L, cobalamin 167 ng/L, and folate 4.5 μg/L. Due to lack of acceptable alternatives, LCIG was continued; i.e. substitution of pyridoxine, cobalamin, and folate resulted in a marked decrease of homocysteine to 32 μg/L after 1 week, and paresthesias remitted within months.

4 | DISCUSSION

The objectives of this study were to determine whether the application of levodopa either with oral or LCIG treatment has an influence on plasma levels of B vitamins and homocysteine in patients with
advanced IPD, and if this is associated with a higher frequency of neuropathy in LCIG than oral pharmacotherapy.

The groups we compared were not significantly different with respect to age, gender, and H&Y; the mean disease duration in the LCIG group was 6 years longer, and LCIG patients scored better than orally treated patients on the UPDRS III, but both differences were statistically insignificant. The significant and most striking difference was that patients treated with LCIG had a more than 2.5-fold higher dose of levodopa/carbidopa per day (LDD).

The higher LDD in the LCIG group was not unexpected, as LCIG allows switching from multiple dopaminergic drugs to levodopa mono-therapy. However, also the LEDD was more than twofold higher than in the oral group demonstrating that LCIG patients required higher dopaminergic stimulation. When comparing pre-LCIG LEDD to post-LCIG LEDD, patients had 1.3-fold higher dopaminergic demand during LCIG. We ascribed this higher dopaminergic demand in the LCIG group not to disease progression, but rather attributed this to the fact that some LCIG patients had 24/7 infusion, and in others subthalmatic deep brain stimulation had been terminated because of intolerable stimulation-induced side effects.

Neuropathy was found in 81% of patients (14 of 17) in whom electrophysiology data was available. It was predominantly axonal in nature. This proportion was much vaster than previously reported prevalences, which range from 5% to ~40% (Ceravolo et al., 2013; Jugel et al., 2013; Merola et al., 2014, 2016; Rajabally & Martey, 2011; Shahrizaila et al., 2013; Toth, Brown, Furtado, Suchowersky, & Zochodne, 2008; Toth et al., 2010). The frequency in our LCIG group was 100% (6 of 6), in the oral group 73% (8 of 11). Why is that so?

Levodopa therapy has been identified to be a risk factor for neuropathy (Mancini et al., 2014; Rajabally & Martey, 2013; Toth et al., 2008); however, dose dependency has not yet been studied systematically: one recent study found that PD patients with neuropathy had an LDD of 1,180 mg, while those without neuropathy had an LDD of 775 mg (Mancini et al., 2014), and like in our study, there were no differences regarding age, gender, and H&Y stage. Our sample, however, had higher LDDs and longer disease durations and therefore very likely a higher exposure to levodopa. This might have contributed to the higher incidence of neuropathy we found. A possible dose dependency is also supported by our observation that patients with LCIG had more severe axonal loss and more nerves affected than the oral group. This finding is exactly the same described in another study examining neuropathy in LCIG treated in comparison to orally treated patients (Jugel et al., 2013).
The frequency of subacute neuropathy during LCIG has not been established yet. In the largest study so far, subacute neuropathy was found in four out of 50 patients (8%) (Mancini et al., 2014). In our clinic, two out of 22 patients receiving LCIG under regular surveillance between 2012 and 2014 had been admitted because of subacute neuropathy, resulting in a similar frequency of 9%. However, subacute neuropathy is not restricted to LCIG, but has been found in orally treated patients, too (Kimber, Blumbergs, & Thompson, 2013), interestingly in patients receiving LDD > 2000 mg/day.

What is the influence of B vitamins?

As shown in Figure 1, the metabolism of levodopa consumes cobalamin, folate, and pyridoxine which act as methyl groups donors; when these substrates are spent, homocysteine accumulates. Therefore, it seems obvious that with increasing doses of levodopa the levels of cobalamin, folate, and pyridoxine decrease, and levels of homocysteine rise. Looking at our results, this is exactly the case—cobalamin and folate were low in both groups, but still within normal range. homocysteine was high above upper limit. This result is in line with previous findings (Ceravolo et al., 2013; Mancini et al., 2014; Merola et al., 2014; Rajabally & Martey, 2011; Santos-Garcia, Macias, Llaneza, Grande, & Fuente-Fernandez, 2011; Toth et al., 2010). All three values did not significantly differ between LCIG and orally treated patients. Cobalamin and folate levels did not correlate with LDD, neither in LCIG nor in orally treated patients. In conclusion, we cannot rule out an influence of low folate and cobalamin levels on the development of neuropathy, but do not consider it as the main cause.

Pyridoxine, however, was low in both groups, but significantly lower in the LCIG group. When analyzed groupwise (i.e., LCIG and oral group separately), statistical analysis did not show a correlation of LDD with pyridoxine levels. Analysis of both groups as a whole, however, showed a significant inverse correlation between pyridoxine levels and LDD (p = .02). A closer look on single data revealed that with an LDD of 2,000 mg/day or higher, virtually all patients developed pyridoxine deficiency irrespective of the route of levodopa application. Again, this perfectly matches previous descriptions of neuropathy occurring at LDDs > 2,000 mg in oral patients (Kimber et al., 2013). Furthermore, we observed a significant correlation between LDD and homocysteine levels, although this was only true for the LCIG-treated patients.

Why is it that of all B vitamins involved in the levodopa metabolism, pyridoxine is lowest in levodopa-treated patients? Why is this probably a dose-dependent phenomenon, and why is it so obvious in LCIG? It has been speculated that something in LCIG might be the cause; for example, the methylcellulose gel could hamper jejunal membrane functions (Jugel et al., 2013). We hypothesize that the reason might be the action of carbidopa in LCIG: Carbidopa is widely known as the decarboxylase inhibitor that inevitably comes along in LCIG and most oral levodopa formulations. Carbidopa irreversibly binds to and permanently deactivates free pyridoxine as well as pyridoxine-dependent enzymes such as many decarboxylases; it thereby depletes the pyridoxine reserve pool (Cellini, Montioli, Oppici, & Voltattorni, 2012; Daidone et al., 2012). Thus, a high dose of levodopa/carbidopa—irrespective of the formulation—may be the cause of pyridoxine deficiency.
deem pyridoxine deficiency induced by metabolizing levodopa as well as induced by irreversible binding of pyridoxine to carbidopa to be two of the major mechanisms. The risk may be extremely high in patients receiving LDDs beyond 2,000 mg, and in those, in which LDD is rapidly increased within a short period of time, as rather often is the case during the initiation of LCIG therapy. We therefore recommend routine assessments of neurographs, pyridoxine, folate, and cobalamin levels in any advanced IPD patients having high LDD in general, and especially before and after initiating LCIG. We furthermore suggest to consider supplementation when severe shortage of pyridoxine is found. In these cases, ongoing monitoring of pyridoxine levels, neuropathic features, and the worsening of parkinsonian symptoms is essential, because high doses of pyridoxine themselves can cause neuropathy.

Future studies are needed to address a couple of urgent questions on this important topic: the most important topic certainly is to establish a clear relationship between pyridoxine levels and neuropathy on the ground of clinical and electrophysiological data, at best in a prospective study design. Furthermore, gathering information on dosage and duration of pyridoxine supplementation is fundamental.

ACKNOWLEDGMENTS

No further acknowledgements.

FINANCIAL DISCLOSURES/CONFLICT OF INTEREST

SL has received travel grants from Abbvie Deutschland. EC and AK have nothing to disclose. DD has nothing to disclose in relation to this study. CS is consultant to Abbvie Deutschland and has received speaker honoraria and travel grants from Abbvie Deutschland.

AUTHOR CONTRIBUTION

SL organized and executed the research project, executed the statistical analysis, wrote the first draft of manuscript, and critically reviewed manuscript. EC organized and executed the research project, critically reviewed the statistical analysis and the manuscript. AK executed the research project, designed and executed the statistical analysis, and critically reviewed the manuscript. DD executed the research project, critically reviewed the statistical analysis, and critically reviewed the manuscript. CS conceptualized, organized, and executed the research project, designed and critically reviewed the statistical analysis, and also reviewed the manuscript.

REFERENCES

Antonini, A., Bondiolotti, G., Natuzzi, F., & Bareggi, S. R. (2010). Levodopa and 3-OMD levels in Parkinson patients treated with Duodopa. European Neuropsychopharmacology, 20, 683–687.
Antonini, A., Isaia, I. U., Canesi, M., Zibetti, M., Mancini, F., Manfredi, L., ... Pezzoli, G. (2007). Duodenal levodopa infusion for advanced Parkinson’s disease: 12-month treatment outcome. Movement Disorders, 22, 1145–1149.

Cellini, B., Montiroli, R., Oppici, E., & Voltattorni, C. B. (2012). Biochemical and computational approaches to improve the clinical treatment of dopa decarboxylase-related diseases: An overview. Open Biochemistry Journal, 6, 131–138.

Ceravolo, R., Cossu, G., Bandettini di Poggio, M., Santoro, L., Barone, P., Zibetti, M., ... Bonuccelli, U. (2013). Neuropathy and levodopa in Parkinson’s disease: Evidence from a multicenter study. Movement Disorders, 28, 1391–1397.

Daidone, F., Montiroli, R., Piaiärdini, A., Cellini, B., Macchiariulo, A., Giardina, G., ... Borri Voltattorni, C. (2012). Identification by virtual screening and in vitro testing of human DOPA decarboxylase inhibitors. PLoS ONE, 7, e31610.

Eggert, K., Schrader, C., Hahn, M., Stamelou, M., Rüssmann, A., Dengler, R., ... Odin, P. (2008). Continuous jejunal levodopa infusion in patients with advanced Parkinson disease: Practical aspects and outcome of motor and non-motor complications. Clinical Neuropharmacology, 31, 151–166.

Fernandez, H. H., Vanagunas, A., Odin, P., Espay, A. J., Hauser, R. A., Standaert, D. G., ... Lenz, R. A. (2013). Levodopa-carbidopa intestinal gel in advanced Parkinson’s disease open-label study: Interim results. Parkinsonism & Related Disorders, 19, 339–345.

Galazky, I., Schoof, J., Stalflort, S., Kupsch, A., Heinze, H. J., & Kluge, C. (2014). Guillaum-Barre/CIDP-like neuropathy in two parkinsonian patients following intestinal levodopa/carbidopa treatment. Parkinsonism & Related Disorders, 20, 125–127.

Grosset, K., Needleman, F., Macphee, G., & Grosset, D. (2004). Switching from ergot to nonergot dopamine agonists in Parkinson’s disease: A clinical series and five-dose drug conversion table. Movement Disorders, 19, 1370–1374.

Hammond, N., Wang, Y., Dimachkie, M. M., & Barohn, R. J. (2013). Nutritional neuropathies. Neurologic Clinics, 31, 477–489.

Jugel, C., Ehlen, F., Taskin, B., Marzinik, F., Muller, T., & Klostermann, F. (2013). Neuropathy in Parkinson’s disease patients with intestinal levodopa infusion versus oral drugs. PLoS ONE, 8, e66639.

Kimber, T., Blumbergs, P., & Thompson, P. (2013). Severe ataxic polyneuropathy associated with chronic levodopa use in Parkinson’s disease. Parkinsonism & Related Disorders, 19, 847–849.

Klostermann, F., Jugel, C., Muller, T., & Marzinik, F. (2012). Malnutritional neuropathy under intestinal levodopa infusion. Journal of Neural Transmission (Vienna), 119, 369–372.

Mancini, F., Comi, C., Oggoni, G. D., Pacchetti, C., Calandrella, D., Coletti Moja, M., ... Antonini, A. (2014). Prevalence and features of peripheral neuropathy in Parkinson’s disease patients under different therapeutic regimens. Parkinsonism & Related Disorders, 20, 27–31.

Merola, A., Romagnolo, A., Zibetti, M., Bernardini, A., Cocito, D., & Lopiano, L. (2016). Peripheral neuropathy associated with levodopa-carbidopa intestinal infusion: A long-term prospective assessment. European Journal of Neurology, 23, 501–509.

Merola, A., Zibetti, M., Rizzone, M. G., Troiano, M., Artusi, C. A., Angrisano, S., ... Lopiano, L. (2014). Prospective assessment of peripheral neuropathy in Duodopa-treated parkinsonian patients. Acta Neurologica Scandinavica, 129, e1–e5.

Miller, J. W., Selhub, J., Nadeau, M. R., Thomas, C. A., Feldman, R. G., & Wolf, P. A. (2003). Effect of L-dopa on plasma homocysteine in PD patients: Relationship to B-vitamin status. Neurology, 60, 1125–1129.

Miodownik, C., Lerner, V., Vishne, T., Sela, B. A., & Levine, J. (2007). High-dose vitamin B6 decreases homocysteine serum levels in patients with schizophrenia and schizoaffective disorders: A preliminary study. Clinical Neuropharmacology, 30, 13–17.

Muller, T. (2008). Role of homocysteine in the treatment of Parkinson’s disease. Expert Review of Neurotherapeutics, 8, 957–967.

Muller, T., Renger, K., & Kuhn, W. (2004). Levodopa-associated increase of homocysteine levels and sural axonal neurodegeneration. Archives of Neurology, 61, 657–660.
Muller, T., van Laar, T., Cornblath, D. R., Odin, P., Klostermann, F., Grandas, F. J., ... Antonini, A. (2013). Peripheral neuropathy in Parkinson’s disease: Levodopa exposure and implications for duodenal delivery. *Parkinsonism & Related Disorders*, 19, 501–507.

Nyholm, D., Askmark, H., Gomes-Trolin, C., Knutson, T., Lennernäs, H., Nyström, C., & Aquilonius, S. M. (2003). Optimizing levodopa pharmacokinetics: Intestinal infusion versus oral sustained-release tablets. *Clinical Neuropharmacology*, 26, 156–163.

Olanow, C. W., Kieburtz, K., Odin, P., Espay, A. J., Standaert, D. G., Fernandez, H. H., ... Antonini, A. (2014). Continuous intrajejunal infusion of levodopa-carbidopa intestinal gel for patients with advanced Parkinson’s disease: A randomised, controlled, double-blind, double-dummy study. *The Lancet Neurology*, 13, 141–149.

Olanow, C. W., Obeso, J. A., & Stocchi, F. (2006). Drug insight: Continuous dopaminergic stimulation in the treatment of Parkinson’s disease. *Nature Clinical Practice Neurology*, 2, 382–392.

Rajabally, Y. A., & Martey, J. (2011). Neuropathy in Parkinson disease: Prevalence and determinants. *Neurology*, 77, 1947–1950.

Rajabally, Y. A., & Martey, J. (2013). Levodopa, vitamins, ageing and the neuropathy of Parkinson’s disease. *Journal of Neurology*, 260, 2844–2848.

Santos-Garcia, D., Macias, M., Llaneza, M., Grande, M., & Fuente-Fernandez, R. (2011). Serum vitamin B12 and folate levels in Parkinson's disease patients treated with duodenal levodopa infusion. *Movement Disorders*, 26, 558–559.

Shahrizaila, N., Mahamad, U. A., Yap, A. C., Choo, Y. M., Marras, C., & Lim, S. Y. (2013). Is chronic levodopa therapy associated with distal symmetric polyneuropathy in Parkinson’s disease? *Parkinsonism & Related Disorders*, 19, 391–393.

Shen, L. (2015). Associations between B vitamins and Parkinson's disease. *Nutrients*, 7, 7197–7208.

Tomlinson, C. L., Stowe, R., Patel, S., Rick, C., Gray, R., & Clarke, C. E. (2010). Systematic review of levodopa dose equivalency reporting in Parkinson’s disease. *Movement Disorders*, 25, 2649–2653.

Toth, C., Breithaupt, K., Ge, S., Duan, Y., Terris, J. M., Thiessen, A., ... Suchowersky, O. (2010). Levodopa, methylmalonic acid, and neuropathy in idiopathic Parkinson disease. *Annals of Neurology*, 68, 28–36.

Toth, C., Brown, M. S., Furtado, S., Suchowersky, O., & Zochedne, D. (2008). Neuropathy as a potential complication of levodopa use in Parkinson’s disease. *Movement Disorders*, 23, 1850–1859.

Urban, P. P., Wellach, I., Faiss, S., Layer, P., Rosenkranz, T., Knop, K., & Weis, J. (2010). Subacute axonal neuropathy in Parkinson’s disease with cobalamin and vitamin B6 deficiency under Duodopa therapy. *Movement Disorders*, 25, 1748–1752.